(AOF) – Theradiag posted a net loss of 56,000 euros in the first half of 2022, compared to a loss of 92,000 euros in the first half of 2021. The operating loss reached 129,000 euros compared to a loss of 178,000 euros a year later. early. The company, which specializes in in vitro diagnostics and theranostics, underlines that its operating loss has been reduced despite a high basis of comparison because the Covid activity had contributed around 150,000 euros to the first half of 2021.
As previously communicated, Theradiag has terminated these antigenic activities in the second half of 2021.
Theradiag has maintained its strategic investments in many areas that will fuel the future growth of the company: commercialization and access to markets, research and development and quality (compliance with the standard for in vitro diagnostic medical devices of the European Union (IVDR) ).
Moreover, without impacting the strategic penetration of particularly important markets, Theradiag’s management will continue to optimize its commercial organization in strategic countries with a view to accelerating a return to strong profitability in the coming months.
As of June 30, 2022, Theradiag generated revenue of €6.3 million, up 14.3%.
On the same date, the group’s cash stood at 6 million euros, compared to 7.1 million euros at December 31, 2021. This level of cash is in line with the company’s roadmap presented on the occasion of its capital increase carried out in October 2021.
In terms of outlook, the company is continuing to apply its strategic plan with a view to achieving a positive structural margin from 2023.
AOF – LEARN MORE
An inevitable race for new blockbusters
The patent for Merck’s star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, since 2019, of the patents for its three star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent only lasts ten to fifteen years. This leads laboratories to withdraw from certain activities. Thus J&J, Pfizer, GSK and, no doubt, Novartis soon prefer to refocus on specialty drugs and abandon any ancillary activity.